Managing Acute Toxicities of CAR T-cell Therapy 

In this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center.
Here are some of the key articles we discussed:
1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”.
pubmed.ncbi.nlm.nih.gov/36989...
2. CAR-HEMATOTOX score:
pubmed.ncbi.nlm.nih.gov/34166...
3. “How I treat cytopenias after CAR T-cell therapy”.
pubmed.ncbi.nlm.nih.gov/36800...
4. Immune Effector Cell-Associated HLH-Like Syndrome (ASTCT):
pubmed.ncbi.nlm.nih.gov/36906...
5. ASTCT consensus grading for CRS and ICANS:
pubmed.ncbi.nlm.nih.gov/30592...
6. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy:
pubmed.ncbi.nlm.nih.gov/35696...
7. Modified EASIX score for predicting CRS and neurotoxicity:
pubmed.ncbi.nlm.nih.gov/34432...